Filter by Category: SENTRY Surveillance
Activity of Aztreonam-Avibactam and Comparators against Difficult-to- Treat Resistant (DTR) Enterobacterales from Patients with Pneumonia or Intra-abdominal Infections (IAI) in European Medical Centers (2020-2024)
Activity of Aztreonam-Avibactam and Comparators against Difficult-to- Treat Resistant (DTR) Enterobacterales from Patients with Pneumonia or Intra-abdominal Infections (IAI) in European Medical Centers (2020-2024). Lead author: Helio S. Sader, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #1273
Activity of manogepix against Candida auris
Activity of manogepix against Candida auris. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3308
Activity of Zosurabalpin Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) Isolates Producing NDM and/or Oxacillinase Enzymes
Activity of Zosurabalpin Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) Isolates Producing NDM and/or Oxacillinase Enzymes. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #1351
Activity of mold-active azole agents against Aspergillus fumigatus clinical isolates nonwildtype to azoles and isolates displaying CYP51 alterations
Activity of mold-active azole agents against Aspergillus fumigatus clinical isolates nonwildtype to azoles and isolates displaying CYP51 alterations. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3323
Activity of Manogepix and Comparator Antifungals Against Mould Isolates Collected from Invasive Infections in Intensive Care Units (ICU) and Non-ICU Settings (2017–2024)
Activity of Manogepix and Comparator Antifungals Against Mould Isolates Collected from Invasive Infections in Intensive Care Units (ICU) and Non-ICU Settings (2017–2024). Lead author: Michael Huband, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3320
Characterization of Candida auris (Candidozyma auris) from a worldwide surveillance program over 12 years
Characterization of Candida auris (Candidozyma auris) from a worldwide surveillance program over 12 years. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3305
Activity of Manogepix and Comparator Antifungal Agents Against Yeast Isolates Collected from Invasive Infections in Intensive Care Unit (ICU) and Non-ICU Settings
Activity of Manogepix and Comparator Antifungal Agents Against Yeast Isolates Collected from Invasive Infections in Intensive Care Unit (ICU) and Non-ICU Settings. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3310
Occurrences by Region and Age Groups and Antifungal Susceptibility Profiles of Opportunistic Filamentous Fungal Pathogens Collected in 8 Years of Global Surveillance
Occurrences by Region and Age Groups and Antifungal Susceptibility Profiles of Opportunistic Filamentous Fungal Pathogens Collected in 8 Years of Global Surveillance. Lead author: Mariana Castanheira, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3323
Isavuconazole activity against moulds in ICU and non-ICU infections
Isavuconazole activity against moulds in ICU and non-ICU infections. Lead author: SJ Ryan Arends, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3303
Comparison of manogepix activity against 2,659 community-acquired and nosocomial mould isolates from the SENTRY Antimicrobial Surveillance Program (2017–2024)
Comparison of manogepix activity against 2,659 community-acquired and nosocomial mould isolates from the SENTRY Antimicrobial Surveillance Program (2017–2024). Lead author: Michael Huband, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3309
Lefamulin Activity against Bacterial Pathogens Typically Causing Community-Acquired Pneumonia Collected from European Medical Centres in 2023 and 2024
Lefamulin Activity against Bacterial Pathogens Typically Causing Community-Acquired Pneumonia Collected from European Medical Centres in 2023 and 2024. Lead author: Helio S. Sader, presented at ESCMID Global 2026, April 20, Munich, Germany
P #1245
Activity of rezafungin against Aspergillus spp.
Activity of rezafungin against Aspergillus spp. Lead author: Marisa L. Winkler, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3304
Isavuconazole activity against moulds in nosocomial and community-acquired infections
Isavuconazole activity against moulds in nosocomial and community-acquired infections. Lead author: SJ Ryan Arends, presented at ESCMID Global 2026, April 20, Munich, Germany
Poster #3312
Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)
Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021). Lead author: CG Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster # 1114
Activity of Cefiderocol and Comparators against US isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020-2021)
Activity of Cefiderocol and Comparators against US isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1099
Activity of Cefiderocol and Comparators against US Enterobacterales, including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020-2021)
Activity of Cefiderocol and Comparators against US Enterobacterales, including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #01091
In Vitro Evaluation of Delafloxacin Activity Against Contemporary European Isolates from Community-Acquired Pneumonia and Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2021)
In Vitro Evaluation of Delafloxacin Activity Against Contemporary European Isolates from Community-Acquired Pneumonia and Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #00563
Activity of Cefiderocol and Comparators against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020-2021)
Activity of Cefiderocol and Comparators against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1063
Bloodstream Infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)
Bloodstream Infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infections Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #391
Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019.
Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019. by Pfaller MA, Huband MD, Shortridge D and Flamm RK. published in J. Glob. Antimicrob. Resist. 2021; 27: 337-351
In Vitro Evaluation of Delafloxacin Activity when Tested against Contemporary Isolates from European Acute Skin and Skin Structure Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2020)
In Vitro Evaluation of Delafloxacin Activity when Tested against Contemporary Isolates from European Acute Skin and Skin Structure Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2020). Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1529
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019)
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019). Lead author: H Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #2020
Bacterial and fungal pathogens isolated from patients with bloodstream infection: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017).
Bacterial and fungal pathogens isolated from patients with bloodstream infection: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). by Pfaller MA, Carvalhaes CG, Smith CJ, Diekema DJ and Castanheira M. published in Diagn. Microbiol. Infect. Dis. 97 (2): 115016, 2020.
Lefamulin Activity against Gram-Positive Pathogens Collected in the 2017 Global SENTRY Antimicrobial Surveillance Program
Lefamulin Activity against Gram-Positive Pathogens Collected in the 2017 Global SENTRY Antimicrobial Surveillance Program. Lead author: S Paukner, presented at ASM/ESCMID 2019, September 3-6, Boston, MA, USA
Poster # T-74
The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program.
The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. by Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS and Jones RN. published in Antimicrob. Agents Chemother. 2019; 63 (7): e00355
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017. by Huband MD, Pfaller MA, Shortridge D and Flamm RK. published in J. Glob. Antimicrob. Resist.: in press, 2019.
Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016).
Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). by Sader HS, Castanheira M, Arends SJR, Goossens H and Flamm RK. published in J. Antimicrob. Chemother. 2019; 74 (6): 1595-1606
Global Trends in Prevalence and Diversity of Carbapenemases Carrying Enterobacteriaceae Identified through SENTRY Antimicrobial Surveillance Program
Global Trends in Prevalence and Diversity of Carbapenemases Carrying Enterobacteriaceae Identified through SENTRY Antimicrobial Surveillance Program. Lead author: LM Deshpande, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-404https://www.jmilabs.com/wp-admin/post.php?post=6561&action=edit#
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Lead author: DJ Diekema, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-400
Fosfomycin Activity against Gram-Negative Isolates from Eastern Europe Collected by the SENTRY Antimicrobial Surveillance Program
Fosfomycin Activity against Gram-Negative Isolates from Eastern Europe Collected by the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-632
Omadacycline In Vitro Activity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the United States and Europe During the 2017 SENTRY Surveillance Program
Omadacycline In Vitro Activity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the United States and Europe During the 2017 SENTRY Surveillance Program. Lead author: MD Huband. Presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-627
Twenty-Year Trends in Antibiotic Susceptibility among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program
Twenty-Year Trends in Antibiotic Susceptibility among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program. Lead author: DJ Diekema, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-425
Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Asia, and Latin America: Results from 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016)
Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Asia, and Latin America: Results from 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016). Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-447
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-2016
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-2016. Lead author: MA Pfaller, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-450
Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program.
Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Castanheira M, Flamm RK and Mendes RE published in J Antimicrob Chemother. 2018: 73 (9); 2314-2322
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. by Pfaller MA, Sader HS, Flamm RK, Castanheira M and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2018; 91 (2): 199-204
In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results.
In vitro activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program results. Lead author: MD Huband, presented in European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1822
Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017).
Evaluation of tedizolid activity against Gram-positive clinical isolates causing pneumonia in Europe and surrounding areas (2017-2017). Lead author: RE Mendes, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1807
Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016.
Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa from the SENTRY Surveillance Program, 1997-2016. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1140
Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016).
Geographic and temporal variation on the frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalised with bacterial pneumonia: Results from 20 years of the SENTRY Program (1997-2016). Lead author: HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0929
The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016).
The worldwide panorama of Acinetobacter baumannii group and Stenotrophomonas maltophilia in the last 20 years: Results from the SENTRY Antimicrobial Surveillance Program (1997-2016). Lead author: AC Gales, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1104
In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program.
In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0599
Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program.
Variations in the occurrence of ESBL, CRE and MDR phenotypes among Enterobacteriaceae isolates: Results from 20 years of the SENTRY Antimicrobial Surveillance Program. Lead author: M Castanheira, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P1073
Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016).
Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016). Lead author HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0102
Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016.
Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016. Lead author: MA Pfaller, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0323
Antipseudomonal activity of piperacillin/tazobactam: More than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
Antipseudomonal activity of piperacillin/tazobactam: More than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). by Jones RN, Stilwell MG, Rhomberg PR and Sader HS published in Diagn. Microbiol. Infect. Dis. 2009; 65(3): 331-334
Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008).
Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). by Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A and Pignatari AC published in Braz J Infect Dis 2009; 13 (2): 90-98
Activity of a long-acting Echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY (2014) Antifungal Surveillance Program.
Activity of a long-acting Echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY (2014) Antifungal Surveillance Program. by Pfaller MA, Messer SA, Rhomberg PR and Castanheira M published in Antimicrob. Agents Chemother. 2017; 61 (3): e02045
Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: Results from SENTRY Antimicrobial Surveillance Program (2011-2014).
Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: Results from SENTRY Antimicrobial Surveillance Program (2011-2014). by Sader HS, Castanheira M, Farrell DJ, Flamm RK, Mendes RE and Jones RN published in Int. J. Antimicrob. Agents. 2016; 48 (2): 144-150
Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program during 2014-2015.
Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program during 2014-2015. by Castanheira M, Griffin MA, Deshpande LM, Mendes RE, Jones RN and Flamm RK published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5623-5624
